238 related articles for article (PubMed ID: 31173117)
1. Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C.
McGlynn EA; Adams JL; Kramer J; Sahota AK; Silverberg MJ; Shenkman E; Nelson DR
JAMA Netw Open; 2019 Jun; 2(6):e194765. PubMed ID: 31173117
[TBL] [Abstract][Full Text] [Related]
2. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C.
Ogawa E; Chien N; Kam L; Yeo YH; Ji F; Huang DQ; Cheung R; Nguyen MH
JAMA Intern Med; 2023 Feb; 183(2):97-105. PubMed ID: 36508196
[TBL] [Abstract][Full Text] [Related]
3. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
4. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
[No Abstract] [Full Text] [Related]
5. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.
Spradling PR; Xing J; Rupp LB; Moorman AC; Gordon SC; Lu M; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Holmberg SD;
J Clin Gastroenterol; 2018 Aug; 52(7):641-647. PubMed ID: 28590325
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A
Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794
[TBL] [Abstract][Full Text] [Related]
7. Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C.
Kalidindi Y; Jung J; Feldman R; Riley T
JAMA Netw Open; 2020 Jul; 3(7):e2011055. PubMed ID: 32692371
[TBL] [Abstract][Full Text] [Related]
8. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
Janjua NZ; Islam N; Wong J; Yoshida EM; Ramji A; Samji H; Butt ZA; Chong M; Cook D; Alvarez M; Darvishian M; Tyndall M; Krajden M
J Viral Hepat; 2017 Aug; 24(8):624-630. PubMed ID: 28130810
[TBL] [Abstract][Full Text] [Related]
9. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
[TBL] [Abstract][Full Text] [Related]
11. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
[TBL] [Abstract][Full Text] [Related]
12. Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort.
Serper M; Forde KA; Kaplan DE
J Viral Hepat; 2018 Feb; 25(2):187-197. PubMed ID: 28845882
[TBL] [Abstract][Full Text] [Related]
13. Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?
Jain MK; Thamer M; Therapondos G; Shiffman ML; Kshirsagar O; Clark C; Wong RJ
Hepatology; 2019 Jan; 69(1):51-63. PubMed ID: 30019478
[TBL] [Abstract][Full Text] [Related]
14. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study.
Wu VC; Huang CH; Wang CL; Lin MH; Kuo TY; Chang CH; Wu M; Chen SW; Chang SH; Chu PH; Wu CS; Lin YS
Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):507-514. PubMed ID: 37170917
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
Alsius M; Ferri MJ; Buxó M; López C; Serra I; Queralt X; Acero D
Gastroenterol Hepatol; 2019 Feb; 42(2):82-89. PubMed ID: 30446175
[TBL] [Abstract][Full Text] [Related]
17. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV).
Walker DR; Pedrosa MC; Manthena SR; Patel N; Marx SE
Adv Ther; 2015 Nov; 32(11):1117-27. PubMed ID: 26538232
[TBL] [Abstract][Full Text] [Related]
18. A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan.
Chen JH; Wu PN; Huang SC; Hsu PJ; Hsu JC
Curr Med Res Opin; 2021 Feb; 37(2):245-252. PubMed ID: 33251875
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
[TBL] [Abstract][Full Text] [Related]
20. Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016.
Jung J; Du P; Feldman R; Kong L; Riley T
J Manag Care Spec Pharm; 2019 Nov; 25(11):1236-1242. PubMed ID: 31663464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]